Prime Medicine Inc., a biotechnology company focusing on innovative genetic therapies, has announced the successful closing of its public offering, raising approximately $144.2 million. The offering consisted of 43,700,000 shares of common stock, including the full exercise of the underwriters' option to purchase an additional 5,700,000 shares, priced at $3.30 per share. Notably, the Cystic Fibrosis Foundation purchased 1,818,181 shares without any discounts or commissions. The offering was managed by TD Cowen and BMO Capital Markets as joint book-running managers. The proceeds are expected to support Prime Medicine's continued development of curative genetic therapies.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。